Dupilumab for Eosinophilic Esophagitis in Children | NEJM

The efficacy and safety of the human monoclonal antibody dupilumab against eosinophilic esophagitis in children younger than 12 years of age are unknown.
Research findings are summarized in a new Quick Take video.
To see the full article, follow this link: nej.md/3VVnWYE
#pediatrics #gastroenterology #immunology #clinicaltrials #nejm